Bladder Cancer

AKY-1189 is currently under investigation in the phase 1b NECTINIUM-2 trial.

Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.

Data showed that measurement of ctDNA and utDNA could identify patients who are most likely to remain cancer-free following systemic therapy.

The combination of enfortumab vedotin plus pembrolizumab extended event-free and overall survival in patients with MIBC who are ineligible for cisplatin-based chemotherapy.

Daniel A. González Padilla, MD, emphasized that shared decision-making is essential, as patients must weigh potential benefits against adverse effects and the possibility of ultimately requiring radical cystectomy or clinical trial participation.

The agent was granted conditional marketing authorization based on data from the phase 2/3 QUILT-3.032 trial.

Christopher P. Filson, MD, MS, highlights the evolving role of urine-based biomarkers in the diagnostic workflow for patients who present with microhematuria.

Christopher P. Filson, MD, MS, highlights a study evaluating the real-world utility of incorporating the CxBladder Triage test to the diagnostic workflow for microhematuria.

Sarah Azari, MD, highlights a prospective study examining the impact of perioperative education on demoralization and sexual function in women with bladder cancer.

The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.

Kristen R. Scarpato, MD, MPH, discusses what level of evidence is necessary to shift the standard of care in BCG-naive NMIBC.

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting.

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Enrollment in the ongoing pivotal QUILT-2.005 trial has now reached 85%.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

The phase 2 study is looking to evaluate nadofaragene firadenovec in combination with the investigational light-activated small molecule TLD-1433 (Ruvidar).

Tom Jayram, MD, discusses the phase 2 SURF302 trial of TYRA-300, a FGFR3-selective inhibitor for FGFR3-altered LG-IR-NMIBC.

Fed Ghali, MD, highlights simulated outcomes of the EV-302 trial when adjusting for use of maintenance avelumab in the control arm.

The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC.

The code, J9282, went into effect on January 1, 2026.